drugset / Trial / NCT05758610
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
NaSingle-groupOpen-labelTreatment
Summary
This Trial is an open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with AML and NHL who previously received standard treatment or are ineligible for standard treatment options.
Timeline
- Start
- 2022-11-04
- Primary completion
- 2025-12
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ETH-155008 | Unknown | 20 mg | Oral |
| Subject | ETH-155008 | Unknown | 40 mg | Oral |
| Subject | ETH-155008 | Unknown | 60 mg | Oral |
| Subject | ETH-155008 | Unknown | 80 mg | Oral |
| Subject | ETH-155008 | Unknown | 100 mg | Oral |